BRPI0820745A2 - Compostos orgânicos - Google Patents

Compostos orgânicos

Info

Publication number
BRPI0820745A2
BRPI0820745A2 BRPI0820745-3A BRPI0820745A BRPI0820745A2 BR PI0820745 A2 BRPI0820745 A2 BR PI0820745A2 BR PI0820745 A BRPI0820745 A BR PI0820745A BR PI0820745 A2 BRPI0820745 A2 BR PI0820745A2
Authority
BR
Brazil
Prior art keywords
organic compounds
compounds
organic
Prior art date
Application number
BRPI0820745-3A
Other languages
English (en)
Inventor
Gerhard Muhrer
Thomas Kieckbusch
Dilraj Singh
Ranjit Thakur
Kurt Schaffleutzel
Norbert Rasenack
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39387173&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0820745(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0820745A2 publication Critical patent/BRPI0820745A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Quinoline Compounds (AREA)
BRPI0820745-3A 2007-12-13 2008-12-11 Compostos orgânicos BRPI0820745A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07123165 2007-12-13
PCT/EP2008/067364 WO2009074666A1 (en) 2007-12-13 2008-12-11 Organic compounds

Publications (1)

Publication Number Publication Date
BRPI0820745A2 true BRPI0820745A2 (pt) 2015-06-16

Family

ID=39387173

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820745-3A BRPI0820745A2 (pt) 2007-12-13 2008-12-11 Compostos orgânicos

Country Status (13)

Country Link
US (1) US20100266696A1 (pt)
EP (1) EP2229148B1 (pt)
JP (1) JP2011506400A (pt)
KR (1) KR20100095587A (pt)
CN (1) CN101896165B (pt)
AU (1) AU2008334547B2 (pt)
BR (1) BRPI0820745A2 (pt)
CA (1) CA2707594C (pt)
ES (1) ES2460576T3 (pt)
PL (1) PL2229148T3 (pt)
PT (1) PT2229148E (pt)
RU (1) RU2496479C2 (pt)
WO (1) WO2009074666A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5893616B2 (ja) 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
BR112013027391A2 (pt) * 2011-05-03 2017-01-17 Chiesi Farmaceutic S P A formulação farmacêutica, frasco e kit
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201307659D0 (en) 2013-04-26 2013-06-12 Korea Coast Guard Commissioner Preparation of drug particles by micronisation
PT107433B (pt) * 2014-01-28 2018-12-04 Hovione Farm S A Processo de redução e controlo do tamanho de partícula
LT3191081T (lt) 2014-09-09 2020-07-10 Vectura Limited Vaisto forma, apimanti glikopiroliatą, būdas ir aparatūra
CN106749008A (zh) * 2015-11-23 2017-05-31 北京九和药业有限公司 一种马来酸茚达特罗的微粉化方法及其应用
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
EP3490533B1 (en) 2016-07-29 2020-05-27 Inke, S.A. Particle size stabilization process
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
EP1920763B2 (en) * 2000-11-30 2022-06-15 Vectura Limited Pharmaceutical compositions for inhalation
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
KR20120091378A (ko) * 2004-03-23 2012-08-17 노파르티스 아게 제약 조성물
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
CN101102740A (zh) * 2005-01-07 2008-01-09 卫材R&D管理有限公司 药用组合物以及其制备方法
WO2006105401A2 (en) * 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
AU2006282122A1 (en) * 2005-08-26 2007-03-01 Astrazeneca Ab A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations

Also Published As

Publication number Publication date
AU2008334547B2 (en) 2011-06-30
CN101896165B (zh) 2013-07-17
PT2229148E (pt) 2014-05-26
US20100266696A1 (en) 2010-10-21
EP2229148B1 (en) 2014-03-05
RU2010128248A (ru) 2012-01-20
RU2496479C2 (ru) 2013-10-27
JP2011506400A (ja) 2011-03-03
PL2229148T3 (pl) 2014-08-29
CA2707594A1 (en) 2009-06-18
KR20100095587A (ko) 2010-08-31
EP2229148A1 (en) 2010-09-22
ES2460576T3 (es) 2014-05-13
WO2009074666A1 (en) 2009-06-18
AU2008334547A1 (en) 2009-06-18
CN101896165A (zh) 2010-11-24
CA2707594C (en) 2015-08-18

Similar Documents

Publication Publication Date Title
DK2240490T3 (da) Organiske forbindelser
BRPI0817434A2 (pt) Composto orgânicos
BRPI0811562A2 (pt) Compostos orgânicos
BRPI0922351A2 (pt) compostos orgânicos
BRPI0922700A2 (pt) Compostos orgânicos
BRPI0922348A2 (pt) Compostos orgânicos
BRPI0922809A2 (pt) compostos orgânicos
BRPI0922808A2 (pt) compostos orgânicos
BRPI0922131A2 (pt) Compostos orgânicos
BRPI0914698A2 (pt) compostos orgânicos
BRPI0913966A2 (pt) compostos orgânicos
BRPI0909417A2 (pt) compostos orgânicos
BRPI0915018A2 (pt) compostos orgânicos
NO20084803L (no) organiske forbindelser
BRPI0718874A2 (pt) Compostos orgânicos
BRPI0718478A2 (pt) Compostos orgânicos
DK2310359T3 (da) Organiske forbindelser
BRPI0921826A2 (pt) compostos orgânicos
BRPI0917574A2 (pt) compostos orgânicos
BRPI0907611A2 (pt) Compostos orgânicos
BRPI0813500A2 (pt) Compostos antivirais
ATE502948T1 (de) Substituierte bicyclolactamverbindungen
BRPI0821086A2 (pt) Compostos inseticidas
BRPI0821401A2 (pt) Compostos orgânicos
BRPI0815042A2 (pt) Compostos de pirazol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.